What is immunitoAI?
Founded in 2020 and headquartered in Bengaluru, immunitoAI operates at the intersection of computational biology and machine learning. The company specializes in in-silico antibody discovery, leveraging advanced artificial intelligence to streamline the identification and validation of therapeutic candidates. By replacing traditional, time-intensive laboratory methods with high-fidelity digital simulations, immunitoAI provides pharmaceutical partners with accelerated, high-accuracy solutions for complex drug development challenges. This technological edge positions the firm as a critical player in the digital transformation of the global biotech sector, effectively reducing the cost and time-to-market for life-saving treatments.
How much funding has immunitoAI raised?
immunitoAI has raised a total of $1M across 1 funding round:
Angel/Seed
$1M
Angel/Seed (2021): $1M with participation from Pi Ventures and Entrepreneur First
Key Investors in immunitoAI
Pi Ventures
Pi Ventures is a venture capital firm focusing on investments in companies that develop artificial intelligence, machine learning, and IoT technologies.
Entrepreneur First
Entrepreneur First is a global talent investor that supports founders in building high-growth technology companies from the ground up.
What's next for immunitoAI?
With this major strategic investment, immunitoAI is poised to scale its operational infrastructure and expand its computational capabilities. The company is expected to focus on enhancing its AI algorithms to handle increasingly complex protein structures, thereby broadening its therapeutic pipeline. As the firm transitions from its initial development phase toward enterprise-level scaling, the focus will likely shift toward establishing high-value partnerships with global pharmaceutical entities. This growth trajectory suggests a long-term commitment to setting new benchmarks in the antibody discovery landscape, utilizing its recent capital infusion to solidify its market leadership in the competitive Indian and international biotech ecosystems.
See full immunitoAI company page
